Demyelinating Disease After Exposure to Tumor Necrosis Factor &#945; Inhibitors: A Case Series in a Tertiary Care Center.

Stienstra, Nicholas; Horton, Joel; Lane, Michael; Kumthekar, Anand; Sathe, Nishad; Sunny, Christy; Yadav, Vijayshree; Deodhar, Atul

Demyelinating Disease After Exposure to Tumor Necrosis Factor α Inhibitors: A Case Series in a Tertiary Care Center.

Stienstra, Nicholas; Horton, Joel; Lane, Michael; Kumthekar, Anand; Sathe, Nishad; Sunny, Christy; Yadav, Vijayshree; Deodhar, Atul.

Afiliación

Stienstra N; From the Division of Arthritis and Rheumatic Diseases.
Horton J; From the Division of Arthritis and Rheumatic Diseases.
Lane M; Department of Neurology, Oregon Health & Science University, Portland, OR.
Kumthekar A; From the Division of Arthritis and Rheumatic Diseases.
Sathe N; From the Division of Arthritis and Rheumatic Diseases.
Sunny C; From the Division of Arthritis and Rheumatic Diseases.
Yadav V; Department of Neurology, Oregon Health & Science University, Portland, OR.
Deodhar A; From the Division of Arthritis and Rheumatic Diseases.

J Clin Rheumatol ; 28(2): e638-e641, 2022 Mar 01.

Article en En | MEDLINE | ID: mdl-34538848

Asunto(s)

Enfermedades Desmielinizantes; Factor de Necrosis Tumoral alfa; Adalimumab/efectos adversos; Enfermedades Desmielinizantes/inducido químicamente; Enfermedades Desmielinizantes/diagnóstico; Etanercept/efectos adversos; Humanos; Centros de Atención Terciaria

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Factor de Necrosis Tumoral alfa / Enfermedades Desmielinizantes Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: J Clin Rheumatol Asunto de la revista: FISIOLOGIA / ORTOPEDIA / REUMATOLOGIA Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google